title: [Escherichia coli associated hemolytic and uremic syndrome: what lessons can be learned after the European epidemic of 2011?].
abstract: Hemolytic and uremic syndrome (HUS) is the most feared complication of infections with enterohemorrhagic Escherichia coli. During summer 2011, Europe was the scene of a large outbreak of shiga-toxin producing E. coli gastroenteritis, occasioning more than 800 cases of HUS, highlighting this public health problem. Last years, many advances have occurred, on the physiopathology, microbiology or therapeutics. We review here these different aspects, from molecular identification of the German bacteria, to the use of targeted therapies as eculizumab in severe forms, or even the major role of complement activation in the physiopathology of HUS.
authors.affiliation: Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France. alemaignen@hotmail.com
authors.forename: Adrien
authors.initials: A
authors.lastname: Lemaignen
authors.forename: Christophe
authors.initials: C
authors.lastname: Ridel
authors.forename: Alexandre
authors.initials: A
authors.lastname: Hertig
authors.forename: Eric
authors.initials: E
authors.lastname: Rondeau
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D004196:Disease Outbreaks; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology*; D005060:Europe; D006463:Hemolytic-Uremic Syndrome / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D054323:Shiga-Toxigenic Escherichia coli / Q000302:isolation & purification*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab